Key result
Flecainide reduced ventricular fibrillation during reperfusion (3 of 15 dogs vs 13 of 25 with placebo) but caused severe proarrhythmic effects during occlusion (13 of 25 dogs vs 1 of 25).
Why the study?
Does flecainide suppress ventricular fibrillation during reperfusion in dogs undergoing coronary artery occlusion and release?
Population
50 pentobarbital-anesthetized dogs undergoing proximal anterior descending coronary artery occlusion for 20…
Comparison
Flecainide acetate 2 mg/kg i.v. vs Saline placebo
Design
Preclinical, randomized, blinded
Follow-up
20 minutes of occlusion followed by reperfusion
Authors
Loading...
Flecainide's proarrhythmic effects during occlusion warrant caution in acute ischemia; leaves open net benefit during reperfusion in this canine model.
RCT (n=50)
blinded
randomized
Does flecainide suppress ventricular fibrillation during reperfusion in dogs undergoing coronary artery occlusion and release?
Absolute Event Rate: 20% vs 52%
In a canine model of acute myocardial ischemia, flecainide exhibited severe proarrhythmic effects during coronary occlusion, causing fatal ventricular fibrillation.
Lederman et al. (1989) conducted an RCT in acute myocardial ischemia (n=50). Flecainide acetate vs. Saline placebo was evaluated on Ventricular fibrillation during reperfusion. Flecainide reduced ventricular fibrillation during reperfusion (3 of 15 dogs vs 13 of 25 with placebo) but caused severe proarrhythmic effects during occlusion (13 of 25 dogs vs 1 of 25).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: